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Abstract 
Background: Medication errors occur frequently in the intensive care unit (ICU) and during care transitions. Chronic 
medication is often temporarily stopped at the ICU. Unfortunately, when the patient improves, the restart of this med-
ication is easily forgotten. Moreover, temporal ICU medication is often unintentionally continued after ICU discharge. 
Medication reconciliation could be useful to prevent such errors. Therefore, the aim of this study was to determine the 
effect of medication reconciliation at the ICU.
Methods: This prospective 8-month study with a pre- and post-design was carried out in two ICU settings in the 
Netherlands. Patients were included when they used ≥ 1 chronic medicine and when the ICU stay exceeded 24 h. 
The intervention consisted of medication reconciliation by pharmacists at the moment of ICU admission and prior to 
ICU discharge. Medication transfer errors (MTEs) were collected and the severity of potential harm of these MTEs was 
measured, based on a potential adverse drug event score (pADE = 0; 0.01; 0.1; 0.4; 0.6). Primary outcome measures 
were the proportions of patients with ≥ 1 MTE at ICU admission and after discharge. Secondary outcome measures 
were the proportions of patients with a pADE score ≥ 0.01 due to these MTEs, the severity of the pADEs and the 
associated costs. Odds ratio and 95% confidence intervals were calculated, by using a multivariate logistic regression 
analysis.
Results: In the pre-intervention phase, 266 patients were included and 212 in the post-intervention phase. The 
proportion of patients with ≥ 1 MTE at ICU admission was reduced from 45.1 to 14.6%  (ORadj 0.18 [95% CI 0.11–0.30]) 
and after discharge from 73.9 to 41.2%  (ORadj 0.24 [95% CI 0.15–0.37]). The proportion of patients with a pADE ≥ 0.01 
at ICU admission was reduced from 34.8 to 8.0%  (ORadj 0.13 [95% CI 0.07–0.24]) and after discharge from 69.5 to 36.2% 
 (ORadj 0.26 [95% CI 0.17–0.40]). The pADE reduction resulted in a potential net cost–benefit of € 103 per patient.
Conclusions: Medication reconciliation by pharmacists at ICU transfers is an effective safety intervention, leading to 
a significant decrease in the number of MTE and a cost-effective reduction in potential harm.
Trial registration Dutch trial register: NTR4159, 5 September 2013, retrospectively registered
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Background
Intensive care unit (ICU) patients are at risk for medica-
tion errors and adverse drug events (ADEs) because of 
the complexity of their conditions, the need for urgent 
interventions and the considerable workload fluctua-
tion of the ICU staff [1, 2]. In addition, certain hospital 
processes carry a high risk for medication errors. One of 
these processes is the transition of care. Approximately 
60% of the medication errors occur at care transitions [3]. 
Lee et  al. [4] showed that clinically significant medica-
tion transfer errors (MTEs) occur in 6 out of 10 patients 
when being shifted from one hospital ward to another. 
The main cause of MTEs is incorrect or incomplete com-
munication, although healthcare providers spend much 
time trying to validate the accuracy of patient medication 
at these interfaces of care [5].
The critical illness at the time of admission usually 
causes long-term medication used at home to be tem-
porarily withheld in the ICU patient [5]. Unfortunately, 
when the patient improves, the restart of this medication 
is easily forgotten. In addition, medication initiated dur-
ing the ICU stay for short-term use, such as gastric acid 
secretion inhibitors [6–8] and antipsychotics [9–13], is 
often inadvertently continued after ICU and even after 
hospital discharge [14].
Among critically ill patients, the medication error rate 
ranges from 1.2 to 947 errors per ICU patient days and 
is an important cause of patient morbidity and mortal-
ity. About 10% of these medication errors are thought to 
result in an ADE [15]. Various interventions have been 
studied to reduce medication errors on the ICU. In a sys-
tematic review by Manias et  al., medication reconcilia-
tion at ICU admission was one of the four interventions 
demonstrating a reduction in medication errors [16]. A 
small number of studies suggest that the incidence of 
medication errors during and after hospitalization can 
be reduced by medication reconciliation at ICU dis-
charge [17–19]. However, these studies have limitations 
such as small sample size, failure to differentiate between 
intentional and unintentional discrepancies and lack of 
assessment of potential clinical impact and/or severity of 
discrepancies.
Studies combining medication reconciliation at ICU 
admission and at ICU discharge are lacking. There-
fore, we designed a pre- and post-intervention study on 
the effect of medication reconciliation by a pharmacist 
on the proportion of patients with medication transfer 
errors (MTEs) at admission to and at discharge from the 
ICU. Furthermore, the effect on the number, severity and 
cost of adverse drug events, as were estimated based on 
the MTE (i.e., potential ADE), was studied.
Methods
Aim
The aim of this study was to determine the effect of a 
medication reconciliation program performed by phar-
macists on the proportion of patients with MTEs both at 
ICU admission and ICU discharge. In addition, the sever-
ity of potential harm of these MTEs was measured, based 
on a potential adverse drug event score (pADE = 0; 0.01; 
0.1; 0.4; 0.6). Furthermore, a cost–benefit analysis was 
performed.
Study design
The TIM (Transfer ICU and Medication reconciliation) 
study was a prospective 8-month intervention study with 
a before and after design in two Dutch hospitals. The pre-
intervention phase consisted of 14  weeks of usual care 
[General Teaching Hospital (GTH): January–April 2013 
and University Hospital (UH): February–May 2014]. 
After a 2-week implementation period, the intervention 
program with medication reconciliation by a pharma-
cist at both ICU admission and ICU discharge started. 
The post-intervention phase consisted of 14  weeks 
(GTH: May–September 2013, UH: July–October 2014). 
A detailed description of the study protocol is published 
elsewhere [19].
Setting and study population
The study was carried out in the Haga Teaching hospital 
in The Hague (GTH; 18 ICU beds) and the Erasmus Uni-
versity Medical Center in Rotterdam (Erasmus MC; UH; 
32 ICU beds).
Patients were included when they used at least one 
medicine at home and when the ICU length of stay 
exceeded 24 h. An ICU discharge and readmission within 
24 h was counted as the same ICU admission.
At discharge, patients were included if they were 
included in the admission part of the study and if they 
survived until at least 24 h after ICU discharge.
Exclusion criteria were: transfer to another hospital, 
both admission and discharge within the same weekend 
(Friday 17:00 until Monday 8:30) and patient’s inability to 
be counseled in Dutch or English. None of the patients 
of the pre-intervention group were part of the post-inter-
vention group.
Since this study did not affect patients’ integrity, a 
waiver from the Zuid Holland Medical Ethics committee 
(METC) and the Erasmus MC METC was obtained. This 
waiver is in line with Dutch trial legislation. Data collec-
tion complied with privacy regulations. Figure 1 gives an 
overview of the study procedures.
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Pre‑intervention phase: usual care
Upon ICU admission, the ICU physician collected infor-
mation about pre-admission medication and registered 
this in the patient data management system of the ICU 
(PDMS). The GTH ICU used Metavision (Itémedical BV, 
Tiel, The Netherlands) and the UH ICU used Care Suite 
8.2 (PICIS Inc., Wakefield, MA, USA). The ICU discharge 
letter contained information about medication in use at 
discharge. Sometimes pre-admission medication and/
or suggestions for medication use after discharge were 
registered.
After transfer, the physician of the admitting ward had 
to transcribe medication orders from the discharge letter 
to the hospital electronic patient records.
The intervention
After ICU admission, a best possible medication history 
(BPMH) was constructed, based on a medication history 
of 6  months from the community pharmacy, available 
hospital medication information and a medication verifi-
cation interview with the patient and/or a representative. 
On the medication history of the community pharmacy, 
the latest date of filling was documented, as well as the 
date of the medication was due to be finished. Based on 
this list, we interviewed the patient and/or caretaker ask-
ing for all medication currently in use, the used dose, etc. 
By combining pharmacy record information with the 
patient information, we were able to get the best possible 
medication list. This is common practice in medication 
reconciliation, based on the WHO High 5 s program [21]. 
The BPMH included drug name, dosage, frequency and 
route—as well as an analysis of discrepancies between the 
medication used at home and prescribed at ICU admis-
sion [22]. The BPMH was documented in the PDMS 
and presented to the ICU physician responsible for the 
patient, helping him or her by explaining the effect of the 
medicine. We supported the physician to make the right 
decision on stopping or continuing. The ICU pharma-
cists also used the BPMH during their patient rounds at 
the ICU.
Shortly before ICU discharge, the ICU pharmacist 
made a discharge medication summary based on the 
BPMH and medication used prior to ICU discharge. For 
each medicine, the ICU physician was prompted for pos-
sible recommendations (i.e., restart, stop and continue). 
During reconciliation of this list with the doctor, the 
pharmacist helped the doctor to make the right advice 
for the ward. As a result, a best possible ICU medication 
Fig. 1 Study procedure pre- and post-intervention. BPMDL-ICU best possible ICU medication discharge list, BPMH best possible medication history, 
BPML-GW24 best possible general ward medication list 24 h after ICU discharge, CPOE/CDS system computerized physician order entry systems with 
clinical decision support, ER emergency room, HIS hospital information system, ICU intensive care unit, OT operating theater, PDMS patient data 
monitoring system, TIM Transfer ICU and Medication reconciliation program
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discharge list (BPMDL-ICU) was made. This was sent as 
an annex of the ICU discharge letter to the physician of 
the receiving ward.
The medication was pre-registered by the pharmacist 
in the Computerized Physician Order Entry/Clinical 
Decision Support (CPOE/CDS) system of the general 
ward the patient was sent to [20]. By doing so, the ward 
doctor was supported by the pharmacist in the transcrib-
ing process. To prescribe the proper after ICU medica-
tion, at the right frequency, the right dose and route, the 
ward doctor only had to check the already pre-registered 
medication and, if found appropriate, simply authorize 
this pre-registered medication.
Outcome measures
The primary outcomes were the proportions of patients 
with ≥ 1 MTE 24 h after ICU admission and 24 h after 
ICU discharge.
An MTE at admission was defined as an unintentional 
discrepancy between BPMH and medication prescribed 
24  h after admission to the ICU. An MTE at discharge 
was defined as an unintentional discrepancy between 
the actual medication chart of the patient and the best 
possible general ward medication list best possible gen-
eral ward medication list 24  h after the ICU discharge 
(BPML-GW24). This BPML-GW24 was based on the 
BPMH, on information in the electronic patient records 
of the hospital and the PDMS, on medication prescribed 
in the CPOE/CDS and, whenever necessary, on inter-
viewing the physician on the ward afterward.
Data collection was performed by trained ICU pharma-
cists. Whether a discrepancy was intentional or not was 
based on information documented in the HIS or the PDMS, 
information given during the medication reconciliation, the 
ICU standards of care and the ICU pharmacist’s interpreta-
tion of the situation. Whenever necessary, the physician on 
the ward was interviewed afterward. In this way, we gave 
the doctor the opportunity to correct the error made. Two 
pharmacists performed a crosscheck on the data. Subse-
quently, all identified MTE underwent a validity check dur-
ing the pADE assessment of the MTEs (see below).
The secondary outcomes were the proportions of 
patients with a pADE score ≥ 0.01 due to an MTE at ICU 
admission and at ICU discharge. A pADE was defined as 
an MTE that could potentially cause harm and/or clini-
cal deterioration and was based on the methodology 
described by Nesbit et  al. [23, 24] using the following 
categories for pADE scores: 0 (zero likelihood of an ADE 
expected by the MTE), 0.01 (very low likelihood of an 
ADE), 0.1 (low likelihood of an ADE), 0.4 (medium likeli-
hood of an ADE) or 0.6 (high likelihood of an ADE).
All MTEs at ICU admission and discharge were pre-
sented blinded and in randomized order to two assessors: 
one hospital pharmacist/clinical pharmacologist and 
one internist/clinical pharmacologist in training, both 
with ICU experience, who independently from each 
other, gave a pADE score for each MTE, based on clini-
cal data of the patient. For MTEs that were given a differ-
ent pADE severity score in the assessments, the assessors 
reached consensus in a meeting.
We measured a total pADE score for every patient 
by summing up the individual pADE scores. These 
pADE scores reflected potential harm per patient in 
the following way: pADE  =  0 (no harm expected), 
0.01  ≤  pADE  >  0.1 (very low likelihood of an ADE), 
0.1  ≤  pADE  >  0.4 (low likelihood of an ADE), 
0.4 ≤  pADE  >  0.6 (medium likelihood of an ADE) and 
pADE ≥ 0.6 (high likelihood of an ADE).
Cost–benefit analysis
The cost avoidance of the TIM program was determined 
by subtracting the average pADE score per patient post-
intervention from the average pADE score pre-inter-
vention. This difference was multiplied by the number 
of patients post-intervention and the relative cost of an 
ADE.
The relative ADE cost price was set at € 1079. This was 
derived from a study by Rottenkolber and was indexed to 
2014 [25].
Costs incurred by the reconciliation process were 
restricted to labor costs of the pharmacist. The direct 
time spent on this intervention was calculated using the 
bottom-up approach, i.e., measuring the number of min-
utes spent per patient by the pharmacist in a represent-
able group of patients. These minutes were multiplied 
with the cost price of one minute of labor and a mar-
ginal markup percentage to account for indirect labor 
time (43%) [26]. The cost price of one minute was valued 
€1.18, based on standardized costs per minute [27].
The costs per patient were multiplied with the total 
number of included patients and the percentages of avail-
ability of the BPMH and the BPMDL-ICU, respectively. 
All costs were based on 2014 Euro cost data.
Sensitivity analysis
A one-way sensitivity analysis was performed for known 
variables in order to determine the effect of varying these 
estimates on the cost–benefit analysis.
The time spent on the intervention was varied by ± 50%. 
Salary costs were varied by using the highest senior hos-
pital pharmacist scale, the lowest point on a basic phar-
macist scale and the salary costs of a pharmacy technician 
with 7  years of experience. For ADE costs, we used the 
study by Bates et al. [28] as alternative to the study by Rot-
tenkolber [25], thus varying the costs to €7177 per ADE. 
Finally, the ADE probability was varied by ± 50% [23, 24].
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Data collection
Data were collected from the hospital electronic patient 
records, PDMS records, CPOE/CDS medication charts, 
BPMH, BPMDL-ICU and BPML-GW24. All data were 
collected in MS Access 2007 (version 2007, Microsoft 
Nederland BV, Amsterdam).
We collected the following TIM intervention charac-
teristics: availability and quality of the BPMH and the 
BPMDL-ICU and the used sources (i.e., patient list, elec-
tronic patient file, medication brought from home and 
pharmacy medication history). The quality of the BPMH 
and the BPMDL-ICU was set at A, B or C [20]. Quality 
A was defined as a reliable reconciliation (based on a 
recent, reliable community pharmacy medication list and 
a reliable verification with patient and/or his representa-
tive), quality B as an intermediate and quality C as a sub-
optimal reconciliation.
The following medication information was collected: 
name of medicine, dose form, medication group [30], 
dose and frequency; prescribed in the PDMS within 24 h 
after admission; prescribed in the CPOE/CDS within 
24  h after the ICU discharge. All discrepancies had an 
intended or non-intended score, a pADE score and a 
discrepancy type (omission, medication added, different 
dose or substitution).
Data analysis
Sample size
The primary outcome of this study was the proportion of 
patients with ≥  1 MTE at admission and discharge from 
the ICU. Based on the literature, the expected proportion 
of patients with MTE between wards within one hospital 
is 62% [4]. Based on a conservative interpretation of this 
study, we took a proportion of 30% in our study. With an 
estimated 50% reduction in errors due to the intervention, 
an alpha of 0.05 and a power of 0.80 calculated the sample 
size was 133. With an estimated mortality of 35%, in each 
measurement phase 205 patients should be included. We 
estimated extra loss of 30% due to the ICU stay less than 
24 h and another 35% loss due to weekend ICU stay. Based 
on the number of ICU admissions per year, this resulted in 
a study period per intervention arm of 7 weeks for Erasmus 
MC and 8 weeks for Haga. To be on the safe side and to 
measure during a robust intervention period, we doubled 
the number of weeks. Therefore, a pre- and post-interven-
tion period of 14 weeks was chosen. Based on an alpha of 
0.05 and a power of 0.80, the calculated sample size was 205 
patients per measurement phase for the primary outcome 
of this study. Based on the number of admissions per year 
and the potential loss due to ICU stays of less than 24 h and 
admission and discharge in one weekend, a pre- and post-
intervention period of 14 weeks was chosen [20].
Statistical analysis
All data were analyzed with SPSS Statistics (version 24, 
IBM Corp., New York).
Patient characteristics pre- and post-intervention were 
compared using the two sample t test for continuous nor-
mally distributed variables, Mann–Whitney U test for 
continuous non-normally distributed variables and Chi-
square test for categorical variables.
For the primary (the proportions of patients with ≥ 1 
MTE at ICU admission and at ICU discharge) and sec-
ondary outcomes (the proportions of patients with a 
pADE score of ≥  0.01 at ICU admission and ICU dis-
charge), adjusted odds ratios and 95% confidence inter-
vals (95% CI) were calculated by using a multivariate 
logistic regression analysis. Potential confounders were 
selected based on a univariate analysis (p  <  0.20) and 
were retained in the multivariate model when they 
changed the beta-coefficient with more than 10%.
Results
Patient, intervention and MTE characteristics
We included 264 patients in the pre-intervention and 
212 in the post-intervention phase at admission and 203 
and 177 at discharge. The two populations differed with 
respect to APACHE IV score [29], percentage of surgical 
patients and specialty (Table 1).
Table  2 shows the intervention characteristics. In 
87.3% of the cases, it was possible to generate a BPMH. 
Of the patients discharged from the ICU 158 (89.3%) had 
a BPMH and 122 (68.9%) had a BPMDL-ICU. We found 
174 (98.3%) of the patients having at least one medication 
reconciliation performed at the ICU.
Table 3 shows the MTE types. Omission was the most 
frequently occurring reason for an MTE in all groups.
Primary outcome: patients with MTE
At admission 45.1% of the patients had at least 1 MTE 
pre-intervention compared to 14.6% in the post-inter-
vention phase, a reduction of 67.6%  (ORadj 0.18 (95% CI 
0.11–0.30), adjusted for APACHE IV).
At discharge 73.9% of the patients had at least 1 MTE 
pre-intervention, compared to 41.2% in the post-inter-
vention phase, a reduction of 44.2%  (ORadj 0.24 [95% CI 
0.15–0.37], adjusted for APACHE IV) (Table 4).
Secondary outcome: patients with potential harm
The proportion of patients with a pADE ≥  0.01 at ICU 
admission was reduced from 34.8 to 8.0%, a reduction of 
77.0% (OR 0.21 [95% CI 0.14–0.33] and  ORadj 0.13 [95% 
CI 0.07–0.24] adjusted for APACHE IV). Five patients 
(1.9%) had a high (≥  0.6) pADE pre-intervention com-
pared to 1 (0.5%) in the post-intervention phase.
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At discharge, the proportion of patients with a 
pADE ≥ 0.01 was reduced from 69.5% to 36.2%, a reduction 
of 47.9% (OR 0.26 [95% CI 0.17–0.40] and  ORadj 0.26 [95% 
CI 0.17–0.40] adjusted for APACHE IV). Nineteen patients 
(9.4%) had a high (≥ 0.6) pADE pre-intervention compared 
to 5 (2.8%) in the post-intervention phase (Table 4).
“Appendix” provides examples of MTE with different 
pADE scores.
Table 1 Patient characteristics
BPMDL-ICU best possible ICU medication discharge list, BPMH best possible medication history, BPML-GW24 best possible general ward medication list 24 h after ICU 
discharge
a T test
b Chi-square test
c Mann–Whitney U test
d 1 person pre-intervention died within 24 h after ICU discharge
e Night = 18.00–06.00 h
f Percentage based on ICU survivors, n = 202
Characteristic Pre‑intervention phase (n = 264) Post‑intervention phase (n = 212) p value
Age (years), mean (SD) 61.3 (14.7) 61.8 (13.4) 0.70a
ICU, GTH 106 (40.2%) 83 (39.2%) 0.88b
Sex, female (%) 98 (37.1%) 89 (42.0%) 0.28b
Days on ICU, median (range) 3 (1–67) 3.5 (1–75) 0.56c
Acute admission, n (%) 168 (63.6%) 125 (59.0%) 0.30b
Surgical, n (%) 94 (35.6%) 105 (49.5%) 0.02b
APACHE IV, mean (SD) 79.1 (32.3) 73.22 (32.9) 0.056a
Died in  ICUd, n (%) 61 (23.1%) 35 (16.5%) 0.10b
Specialty, n (%) 0.01b
 Internal medicine 26 (9.8%) 23 (10,8%)
 Cardiology 58 (22.0%) 30 (14.2%)
 Neurosurgery 14 (5.3%) 21 (9.9%)
 Pulmonology 16 (6.1%) 16 (7.5%)
 Neurology 31 (11.7%) 16 (7.5%)
 Surgery 75 (28.4%) 66 (31.1%)
 Gastroenterology 23 (8.7%) 14 (6.6%)
 Hematology 13 (4.9%) 6 (2.8%)
 Rest 8 (3.0%) 20 (9.4%)
Admitted from, n (%) 0.45b
 Emergency room 68 (25.8%) 46 (21.7%)
 Community 1 (0.4%) 4 (1.9%)
 Ward 97 (36.7%) 79 (37.3%)
 Operating theater 88 (33.6%) 76 (35.8%)
 Other hospital 10 (3.8%) 7 (3.3%)
Admission at  nighte, n (%) 86 (32.6%) 70 (33.0%) 0.67b
Admission in weekend, n (%) 68 (25.8%) 44 (20.8%) 0.22b
Discharge at  nighte,f, n (%) 13 (6.4%) 12 (6.8%) 0.88b
Discharge in  weekendf, n (%) 35 (17.2%) 28 (15.8%) 0.71b
No of medications on
 BPMH (median) 5 (1–24) 6 (1–20) 0.69c
 BPMDL-ICU (median) – 11 (1–25)
 BPML-GW24 (median) 11 (1–25) 10.0 (4–23) 0.61c
Total no of medications on
 BPMH 1655 1359
 BPML-GW24 2212 1886
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Cost–benefit analysis
Table 5 shows a positive cost–benefit ratio of 2.48, lead-
ing to a potential net cost–benefit of €103 per patient. 
Costs of the intervention were € 7476 at admission and 
€ 7256 at discharge. At admission 7.33 pADEs were pre-
vented, leading to a cost avoidance of € 7911 at admis-
sion. At discharge 26.59 pADEs were prevented, leading 
to a cost avoidance of € 28,687. In the sensitivity analy-
sis, the cost–benefit remained positive in all scenarios. 
The largest variance was found in costs assigned to an 
ADE (ADE range, adjusted to 2014: € 1079 (Rottenkolber 
[25])–€7177 (Bates [25]).
Discussion
In this prospective intervention study, the proportion 
of patients with ≥ 1 medication transfer error (MTE) at 
ICU admission was reduced from 45.1 to 14.6% and at 
discharge from 73.9 to 41.2%. At admission 7.33 poten-
tial adverse drug events (pADEs) were prevented and at 
discharge 26.59 pADEs. The cost–benefit ratio of 2.48 
indicates that €1000 (= 14.2 h) spent on a pharmacist for 
medication reconciliation at the ICU will avoid a cost of 
€2480. This equals a potential net cost saving of €103 per 
patient, suggesting that medication reconciliation by a 
pharmacist is cost beneficial.
Although the MTE and pADE burden was the high-
est at discharge of the ICU, the TIM intervention was 
most effective at ICU admission. There are two possible 
explanations for this. First, at ICU admission, the BPMH 
was given to the ICU physician who could directly act 
by changing the prescribed medication in the PDMS, 
while at ICU discharge the intervention was more indi-
rect since the BPMDL-ICU was not reviewed with the 
Table 2 Intervention characteristics
BPMDL-ICU best possible ICU medication discharge list, BPMH best possible 
medication history, BPML-GW24 best possible general ward medication list 24 h 
after ICU discharge
a Adjusted for indirect labor time
b The percentage patients who survived the ICU and were discharged to the 
general ward and had a BPMH available
Admission Patients (n = 212)
BPMH available (n, %) 185 (87.3%)
Quality BPMH
 A = optimal 129 (60.8%)
 B = no (proper) conversation 79 (37.3%)
 C = poor quality 4 (1.9%)
Reconciliation BPMH with
 Patient 76 (35.8%)
 Caregiver 60 (28.3%)
Minutes per BPMH (incl. + 43%a) 24.0 (34.3)
Used sources
 List from patient 9 (4.2%)
 Emergency room electronic patient file 18 (8.4%)
 Home medication 11 (5.2%)
 Community pharmacy 190 (89.6%)
 Other institution 24 (11.3%)
Discharge Patients (n = 177)
BPMDL-ICU available (n, %) 122 (68.9%)
BPMH  availableb (n, %) 158 (89.3%)
BPMH and/or BPMDL-ICU available (n, %) 174 (98.3%)
Quality BPMDL-ICU
 A = optimal 119 (67.2%)
 B = no (proper) conversation 4 (2.3%)
 C = poor quality 1 (0.6%)
Minutes per BPMDL-ICU (incl. + 43%a) 29.4 (42.0)
Table 3 MTE characteristics
MTE medication transfer error
MTE types Pre‑intervention phase Post‑intervention phase p value
MTE = 206 MTE = 39
Admission
Omission 163 (79.1%) 25 (64.1%) 0.11
Drug added 10 (4.9%) 1 (2.6%)
Different dose 28 (13.6%) 10 (25.6%)
Substitution 4 (1.9%) 2 (5.1%)
No discrepancy 1 (0.5%) 1 (2.6%)
MTE = 399 MTE MTE = 122
Discharge
Omission 288 (72.2%) 88 (72.1%) 0.83
Drug added 39 (9.8%) 10 (8.2%)
Different dose 51 (12,8%) 15 (12.3%)
(Re)start 1 (0.3%) 0 (0.0%)
Substitution 20 (5.0%) 9 (7.4%)
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physician of the admitting ward, but with the ICU phy-
sician. Second, the ICU discharge service was delivered 
less frequently (87.3 versus 70.1%), as for this part of the 
TIM program, it was more challenging to reach the ICU 
physician in time; the actual time frame at discharge was 
in general short, whereas the discharge reconciliation 
process was complex and therefore time-consuming.
Compared to Provonost et al. [17] who found a reduc-
tion in almost 94% MTE at ICU discharge, the effect of 
our TIM program seems far less with 41.2%. However, 
Provonost’s study measured the effect at the information 
written on the ICU discharge order and their medication 
reconciliation was not based on information from the 
home pharmacy.
Strengths of our study include the prospective study 
design and the carefully designed TIM intervention 
program. Other strengths of our study were the use of 
unintentional discrepancies (MTE) and their potential 
for harm (pADE) as outcome measures as well as a cost–
benefit analysis. Finally, our study was performed at two 
different settings, which makes our results robust.
This study has a number of limitations as well. First, 
the study did not include a hospital setting in which the 
PDMS and the CPOE/CDS systems were an integrated 
Table 4 Medication transfer errors (MTE) and potential adverse drug event (pADE) outcomes
MTE medication transfer error, pADE potential adverse drug event
a Adjusted for APACHE IV
b Average MTE per patient at intervention subtracted by score pre-intervention and multiplied with number of patients at intervention
c Average pADE score per patient at the intervention subtracted by score pre-intervention and multiplied with number of patients at intervention
MTE and pADE outcomes Pre‑intervention phase Post‑intervention phase ORaadj [CI 95%]
Patients = 264 Patients = 212
ICU admission
 Patients with ≥ 1 MTE (n, %) 119 (45.1%) 31 (14.6%) 0.18 [0.11–0.30]
 Patients with ≥ 0.01 pADE (n, %) 92 (34.8%) 17 (8.0%) 0.13 [0.07–0.24]
  Without harm (pADE = 0) 27 (22.7%) 14 (45.2%)
  Very low harm expected (0.01 ≤ pADE > 0.1) 35 (29.4%) 6 (19.4%)
  Low harm expected (0.1 ≤ pADE > 0.4) 45 (37.8%) 7 (22.6%)
  Medium harm expected (0.4 ≤ pADE > 0.6) 7 (5.9%) 3 (9.7%)
  High harm expected (pADE ≥ 0.6) 5 (4.1%) 1 (3.2%)
MTE (n, per patient) 206 (0.78) 39 (0.18)
pADE (n, per patient) 12.58 (0.05) 2.77 (0.01)
Medications with MTE (% of all medications) 12.3% 2.9%
Medications with ≥ 0.01 pADE (n, % of all medications) 146 (8.7%) 20 (1.5%)
Total prevented  MTEb (n, per patient) 126.4 (0.60)
Total prevented  pADEc (n, per patient) 7.33 (0.03)
Patients = 203 Patients = 177
ICU discharge
 Patients with ≥ 1 MTE (n, %) 150 (73.9%) 73 (41.2%) 0.24 [0.15–0.37]
 Patients with ≥ 0.01 pADE (n, %) 141 (69.5%) 64 (36.2%) 0.26 [0.17–0.40]
  Without harm (pADE = 0) 9 (6.0%) 9 (12.3%)
  Very low harm expected (0.01 ≤ pADE > 0.1) 33 (22.0%) 28 (38.4%)
  Low harm expected (0.1 ≤ pADE > 0.4) 56 (37.3%) 25 (34.3%)
  Medium harm expected (0.4 ≤ pADE > 0.6) 33 (21.9%) 6 (8.2%)
  High harm expected (pADE ≥ 0.6) 19 (12.7%) 5 (7%)
MTE (n, per patient) 399 (1.97) 122 (0.69)
pADE (n, per patient) 41.97 (0.21) 9.55 (0.05)
Medications with MTE (% of all medications) 17.9% 6.4%
Medications with ≥ 0.01 pADE (n, % of all medications) 14.9% (333) 5.4% (102)
Total prevented  MTEb (n, per patient) 225.9 (1.28)
Total prevented  pADEc (n, per patient) 26.59 (0.15)
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part of the same electronic patient record. Therefore, a 
certain part of our MTEs could be due to transcription 
problems. However, because of all medication changes 
in the ICU, the ward physician has to review all medica-
tion after ICU discharge anyway, regardless of the CPOE/
CDS situation. Second, clear documentation of reasons 
why home medication was withheld was generally lack-
ing. This made the discrepancy assessment complicated. 
We overcame this problem by a thorough methodol-
ogy of strict scoring and crosschecking. Third, the study 
measured potential ADEs, rather than actual ADEs and 
the extent of long-term effects of the harm caused by the 
MTE could not be determined, since we didn’t follow-up 
after hospital discharge. Fourth, as our cost–benefit anal-
ysis was based on reduction in potential ADE, instead of 
actual ADE, our cost–benefit analysis was preliminary. 
For this reason, we used the most conservative ADE price 
and we performed a sensitivity analysis, which remained 
positive in all scenarios. Finally, a before-after design is 
less robust than a randomized controlled design, but for 
this safety intervention a randomized controlled design is 
not feasible.
In our opinion, the success of our program was based 
on a combination of three elements: (1) focus on the 
transition, (2) a structured approach for the collection of 
medication history and discrepancy analysis, combined 
with (3) the ICU pharmacist knowledge and skills. We 
assume that this program can be as successful in other 
ICUs. Although we do not know the single impact of 
the different elements of our program, we think for the 
medication reconciliation part at ICU admission this 
could probably be performed by trained pharmacy tech-
nicians as well. However, as we found the discharge part 
far more complicated to properly perform (e.g., being 
able to interpret all ICU protocols, continuation of high 
risk medication, restarting a patient’s medication), we 
find that a pharmacist with specific ICU knowledge and 
understanding of the discharge process is necessary for 
the discharge process. As we found our intervention to 
have a positive cost–benefit ratio, we recommend hospi-
tals to consider having an ICU pharmacist for medication 
reconciliation at the ICU.
Our results indicate that more focus on post-ICU care 
is necessary to further reduce inappropriate medica-
tion discontinuation and unintentional continuation of 
ICU medication after critical illness. This is in line with 
Bell et  al. [5], who stated that discharge from the ICU 
is a time when longer-term treatment goals should be 
Table 5 Cost–benefit and sensitivity analysis
ADE adverse drug event
a Based on 2014 Euro cost data
Cost–benefit analysis
Calculation Costs and benefits Outcomea
1. Costs of SERVICE (Pharmacist labor)
 Admission −€ 7476
 Discharge −€ 7256
2. Cost avoidance
 Admission € 7911
 Discharge € 28,687
3. (= 2–1) Net cost–benefit
 During intervention period € 21,868
 Per patient (at admission) € 103
4. (= 2:1) Cost–benefit ratio 2.48
Sensitivity analysis
Variable Variation Cost–benefit ratio
Time + 50% minutes per intervention 1.66
− 50% minutes per intervention 4.96
Salary Highest point on hospital pharmacist scale 2.22
Lowest point on hospital pharmacist scale 3.55
Pharmacy technician (7th year) 7.73
ADE probability − 50% 1.24
50% 3.73
ADE cost Based on Bates et al. [28] 16.52
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contemplated and usual medications should be restarted 
or reconsidered.
Future research should focus on further development 
of the combined ICU medication reconciliation process, 
for example by introducing ICT tools. Furthermore, the 
clinical and financial effect of medication reconciliation 
should be measured based on actual harm instead of 
MTEs and pADEs.
Conclusions
Medication reconciliation by a pharmacist at ICU admis-
sion and discharge was an effective safety intervention, 
improving the continuity of care for the ICU patient, 
leading to a significant decrease in the number of MTEs 
and a cost-effective reduction in potential harm.
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